Lead program
Our lead program in hematologic malignancies targets an "Eat Me" signal upregulated on B cell and myeloid tumors.
Pipeline
CERo is building a broad pipeline of CER T-cell products.
| Product Candidates | Indications | Stages |
|---|---|---|
| Home Malignancies | ||
| CER-1236 (Lead Program) |
Hematology | IND-enabling |
| Solid Tumors | ||
| CER-1236 | Solid Tumor | Pre-Clinical |